Market Trends of Ambulatory Infusion Centers Industry
The Oncology Segment is Expected to Witness Significant Growth Over the Forecast Period
The oncology segment by application covers the application of drug administration through infusion or intravenous routes at ambulatory infusion centers. There are a lot of drugs for chemotherapies that are given as an infusion or injection at these facilities. The growing demand for ambulatory infusion therapy for cancer, coupled with growing cancer cases in recent years, is the major driving factor responsible for the growth of the oncology segment. For instance, as per the World Health Organization (WHO), there were an estimated 20 million new cancer cases in 2022 across the globe.
Moreover, the launch of targeted infusion therapy for cancer in recent years is also fueling the growth of the oncology segment in the global ambulatory infusion centers market. For instance, in August 2022, the US FDA approved the first targeted therapy trastuzumab deruxtecan (T-DXd) of AstraZeneca, for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed.
Additionally, companies have focused more on technological advancements in infusion therapy for cancer treatment, which is also one of the major driving factors responsible for the growth of the oncology segment. These technological advancements, such as smart pump can be observed in intelligent pump integration, remote monitoring, etc., are some of the major driving factors to propel the segment's growth in recent years. In March 2022, MicroPort Lifesciences received marketing approval from China's National Medical Products Administration (NMPA) for its independently developed new AutoEx Chemotherapy Infusion Pump (AutoEx). AutoEx is a portable infusion pump with a dual CPU control system and dual power supply that can provide high-precision drug delivery control and improve patient comfort safely and reliably.
Hence, the above-mentioned factors, such as the rising prevalence of cancer across the globe, recent product approvals for target infusion therapy, and technological advancements in infusion therapy, will drive the growth of the oncology segment in the upcoming years.
North America is Expected to Dominate the Ambulatory Infusion Centers Market
North America is expected to dominate the market due to factors such as the increasing prevalence of cancer and cardiovascular diseases, increasing government support programs for ambulatory infusion centers, and growing demand for ambulatory infusion suites in the region. For instance, as per the American Cancer Society, Inc., an estimated 2.1 million new cancer cases are expected to be reported in 2024 in the United States. Also, as per the Canadian Cancer Society, there were 239,100 new cancer cases and 86,700 cancer deaths were reported in Canada in 2023.
Moreover, rising product approval and the launch of infusion products for cancer and other chronic diseases are also fueling the growth of the North America Ambulatory Infusion Centers Market. In November 2023, the US FDA approved AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) in the US for the treatment of adult patients with hormone receptor (HR)-positive HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN).
Therefore, owing to the factors mentioned above, the growth of the studied market is anticipated in the North American region.
